Novel ADC Promising in Certain Non-Squamous Lung Cancers Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
More Data in Support of Surgery for Malignant Pleural Mesothelioma Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancer LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLC Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesothelioma Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
Durable Response with Immunotherapy Combos in NSCLC with Brain Metastases Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
Dual Immunotherapy Boosts Survival in Metastatic NSCLC Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patients Patients often did not consult with radiation or medical oncologists Sep 09, 2021
Second-Line Combo Fails to Improve Survival in SCLC No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021
High Response Rate in Non-Small Cell Lung Cancer With RET Inhibitor Responses in 66-80% of patients from China confirm activity of pralsetinib Sep 09, 2021
TROP2 Antibody-Drug Conjugate Shows Promise in Lung Cancer Disease control observed in over two-thirds of patients at selected dose Sep 08, 2021
KRAS Inhibitor Continues to Impress in NSCLC Sotorasib yielded deep and durable responses in over one-third of patients Feb 01, 2021
Nab-Paclitaxel as Possible Option for Relapsed NSCLC Noninferior to docetaxel for OS, though impact on clinical practice questioned Feb 01, 2021
Promising Data for Preop Checkpoint Inhibition in NSCLC Major response rate of 21%, encouraging survival with single-agent atezolizumab Jan 31, 2021
First-Ever Survival Bump in Relapsed Mesothelioma OS, PFS improved with nivolumab, but questions remain about alternatives, biomarkers Jan 30, 2021
Dual Checkpoint Blockade No Help in PD-L1-High NSCLC Single-agent pembrolizumab wins out as first-line therapy for advanced disease Jan 30, 2021
COVID Affects Cancer Care, Patients' Mental Health Studies: fewer diagnoses, more severe disease, worse outcomes, distressed patients Jan 29, 2021
Chemo-Free Regimen Boosts OS in Mesothelioma Big advantage for nivolumab-ipilimumab in nonepithelioid tumors drives advantage over chemo Aug 09, 2020
Another ALK Drug Tops Crizotinib in First-Line NSCLC Ensartinib doubled PFS over older standard, with improved CNS activity Aug 08, 2020
Anti-PD-1/L1 for NSCLC Sparks Talk of the 'C' Word Unprecedented survival at 3 and 5 years, but investigators reluctant to say "cure" Sep 10, 2019
'Dirtier' Drugs Step Aside in RET-Positive NSCLC Over two-thirds of patients respond to selective RET inhibitor Sep 09, 2019
TMB in Lung Cancer: 'Not Ready for Prime Time' No association between tumor mutational burden and outcomes in three trials Sep 09, 2019
More Evidence that Screening Cuts Lung Cancer Deaths Significantly lower risk in men and women Sep 26, 2018
Newer ALK Inhibitor Tops Standard in NSCLC Significant improvement in PFS with brigatinib after short follow-up Sep 26, 2018
Anti-PD-L1 Drug Boosts Survival in Stage III NSCLC New standard of care for patients with inoperable disease Sep 26, 2018
Add-On Keytruda Boosts OS in Advanced Squamous Lung Cancer Benefit seen across all subgroups, PD-L1 expression levels Sep 25, 2018
No Survival Benefit with Cranial RT for NSCLC Better disease-free survival, fewer brain mets Sep 25, 2018
